FDA reviews Merck & Co's Keytruda in new 'tumour agnostic' u...

Merck & Co’s Keytruda cancer immunotherapy could be set for another indication, which could open up for use in all cancer patients whose tumours have a certain genetic biomarker.

Cancer Research UK cuts research funding as COVID-19 hits in...

Cancer Research UK has cut funding to its research activities, as the charity faces a cut to its income by up to a quarter in the next financial year because of the impact of the coronaviru

BMS' big merger bet is still on with latest CAR-T filing

Bristol-Myers Squibb and development partner bluebird bio have filed their multiple myeloma CAR-T with the FDA, the final part of a three-drug “bet” that was a sweetener following its $74 b

AZ firms up immuno-oncology imaging deal with ImaginAb

FDA approves AZ Imfinzi in new lung cancer use

AstraZeneca has reported a double win after the FDA approved its Imfinzi for a form of lung cancer, and it stopped a trial of its Farxiga after showing “overwhelming efficacy” in chronic ki

New combination trial firms up Venclexta’s prospects in AML